Semaglutide, explained for people considering it
The most established of the modern weight-loss injections. Here is what a course of treatment actually involves, how the dose is built up, and what the pivotal study measured over 68 weeks — with sources you can check.
Wegovy / Ozempic · GLP-1 receptor agonist, once-weekly injection[1]
What treatment actually looks like
Treatment is a once-weekly injection you give yourself at home with a prefilled pen. The first months are deliberately gradual: doses start low and step up roughly every four weeks, so most of the early period is about letting your body adjust rather than chasing the scale. The study curve below shows why patience is part of the design — average weight loss was measurable from the first assessment at week 4 and built steadily over more than a year before leveling off.
How the dose builds
The FDA-labeled schedule starts at 0.25 mg weekly — a dose that exists to build tolerance, not to drive weight loss — and steps up through 0.5, 1.0 and 1.7 mg before settling at the 2.4 mg maintenance dose — the final step in the schedule below. A provider can hold any step longer if side effects need time to settle; slower is common and clinically normal.[2]
Doses step up gradually so the body can adjust — moving up is never automatic. A provider confirms each step based on how treatment is going, and slower schedules are common when side effects need more time to settle.
Medication level and measured weight change, together
These two lines tell the story most pages leave out. The teal line models how medication actually accumulates in your body: with a half-life of about a week, each injection stacks on the last, and every dose-escalation step lifts the level to a new plateau. The green line is what the STEP 1 trial measured across 68 weeks in nearly two thousand adults — average weight change, alongside the placebo group for honest contrast.[1]
Teal line: an illustrative pharmacokinetic model of once-weekly Semaglutide following the labeleddose-escalation schedule (relative units — the shape, not a measurement). Green line: mean body-weight change reported in STEP 1 (2.4 mg arm, n=1306, of 1,961 randomized). Intermediate points are approximate readings from the trial's published weekly figure; the week-68 values are the trial's primary estimates. The study reported weight loss from the first assessment at week 4, reaching its lowest point around week 60. Study means describe study populations — individual results vary, and treatment decisions belong to you and a licensed provider.
What the research measured
STEP 1 enrolled 1,961 adults with a BMI of 30 or higher (or 27 with a weight-related condition) and no diabetes. Over 68 weeks, the semaglutide group averaged a 14.9% reduction in body weight versus 2.4% with placebo. More than two-thirds lost at least 10% of their body weight, and about half lost 15% or more.[1]
Side effects, honestly
- Gastrointestinal effects are the most common — nausea, diarrhea, vomiting, constipation — and the labeled step-up schedule exists specifically to minimize them.
- The label carries a boxed warning about thyroid C-cell tumors seen in rodents; people with a personal or family history of medullary thyroid carcinoma or MEN 2 should not take it.
- Less common but serious risks include pancreatitis and gallbladder disease — reasons a provider reviews your history first and stays reachable during treatment.
- It should not be combined with other GLP-1 medications, and pregnancy is a reason to stop — discuss timing with your provider if that is on the horizon.
Source: FDA prescribing information[2]. Not a complete list — a provider reviews your health history before any prescription.
Common questions
How fast does semaglutide start working?
In the pivotal study, average weight loss was observed from the first assessment at week 4 and kept deepening over months — the study group was still losing at the one-year mark. Early weeks are intentionally spent at doses chosen for tolerance, not maximum effect.
Why does the dose increase so slowly?
Per the FDA label, the escalation schedule exists to minimize gastrointestinal side effects. Moving up is a decision your provider confirms at each step, and staying longer at a step is normal.
What happens if I stop taking it?
Because the medication has a half-life of about a week, the label notes it remains in circulation for roughly five to seven weeks after the last dose. What happens to your weight after that is something to plan for with your provider — obesity treatment is generally approached as long-term care, not a short course.
Is Wegovy the same as Ozempic?
Both are semaglutide. Wegovy is the formulation FDA-approved for chronic weight management at doses up to 2.4 mg weekly; Ozempic is approved for type 2 diabetes. A licensed provider determines which, if either, is appropriate for you.
Wondering if semaglutide is right for you?
A licensed provider reviews your health history and gives you a straight answer — including no, when it's the right answer.
References
- 1.Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021;384:989-1002. doi:10.1056/NEJMoa2032183. https://www.nejm.org/doi/full/10.1056/NEJMoa2032183
- 2.WEGOVY (semaglutide) injection — FDA Prescribing Information, via DailyMed (dosage & administration; clinical pharmacology). https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f5e548d0-cc79-4c34-a3f5-e20a5b8b6564
This page is educational information, not medical advice, and reading it does not create a provider relationship. Whether any medication is appropriate for you is a decision for you and a licensed clinician who knows your health history. Study results describe study populations under trial conditions; individual results vary. If you experience concerning symptoms while on any medication, contact your clinician or seek urgent care.